Table 2. Propensity score matched patient characteristics.
| Patient or tumor characteristic | Adjuvant chemotherapy | No adjuvant therapy | P |
|---|---|---|---|
| n | 46 | 92 | |
| Median age (range), years | 59.2 (38.1–79.2) | 62.9 (30.0–82.5) | 0.146 |
| Sex | 0.640 | ||
| Male | 37 | 77 | |
| Female | 9 | 15 | |
| Ethnicity | 0.335 | ||
| Caucasian | 42 | 89 | |
| Other | 4 | 3 | |
| Location | 0.747 | ||
| Upper 1/3 | 0 | 1 | |
| Middle 1/3 | 2 | 7 | |
| Lower 1/3 | 25 | 53 | |
| GE-junction | 19 | 31 | |
| Histology | 0.475 | ||
| Adenocarcinoma | 42 | 81 | |
| Squamous cell carcinoma | 2 | 9 | |
| Mixed | 2 | 2 | |
| ypT-classification | 0.749 | ||
| ypT0 | 6 | 8 | |
| ypT1 | 4 | 16 | |
| ypT2 | 14 | 23 | |
| ypT3 | 21 | 41 | |
| ypT4 | 1 | 4 | |
| ypN-classification | 0.427 | ||
| ypN0 | 10 | 31 | |
| ypN1 | 28 | 48 | |
| ypN2 | 5 | 11 | |
| ypN3 | 3 | 2 | |
| Neoadjuvant chemotherapy | 1.000 | ||
| Platinum + 5-FU/capecitabine | 41 | 83 | |
| Platinum + taxane | 5 | 9 | |
| Pathologic response | 0.921 | ||
| Complete | 3 | 7 | |
| Partial* | 24 | 51 | |
| None | 19 | 34 | |
| Margin status | 1.000 | ||
| Negative | 39 | 78 | |
| Microscopic positive | 7 | 14 |
*, partial was defined as a lower T-classification than seen on endoscopic ultrasound or node negativity with reported nodes positive on endoscopic ultrasound. No patient or tumor characteristics were found to be significantly associated with adjuvant chemotherapy based on case-control analysis with a 2:1 propensity score matching algorithm.